AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18071011 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ciclesonide 320 microg daily for 3 weeks
Number of subjects: 26
Study 18071011 — intervention group
Group type: COMPARATOR
Intervention: Inhaled ciclesonide 40 microg daily for 3 weeks
Number of subjects: 26
Study 18071011 — intervention group
Group type: COMPARATOR
Intervention: Inhaled ciclesonide 80 microg daily for 3 weeks
Number of subjects: 26
Study 16011141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 114
Study 16011141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 114
Study 14697160 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam (4 g/8 h iv)
Number of subjects: 150
Study 14697160 — intervention group
Group type: COMPARATOR
Intervention: ceftriaxone (2 g/24 h iv) plus ornidazole (1 g/24 h iv)
Number of subjects: 150
Study 10579472 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride (500 mg) plus ketoconazole (100 mg twice daily for 3 days)
Number of subjects: 9
Study 10579472 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride (500 mg) plus fluvoxamine (25 mg twice daily for 2 days)
Number of subjects: 9
Study 8619360 — intervention group
Group type: EXPERIMENTAL
Intervention: iobitridol 350
Number of subjects: 40
Study 8619360 — intervention group
Group type: COMPARATOR
Intervention: iopamidol 370
Number of subjects: 40
Study 2047064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 (25-mg tablets orally every 8 hours for 72 hours)
Number of subjects: 59
Study 2047064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same regimen as vitamin B6)
Number of subjects: 59
Study 2047064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Number of subjects: 59
Study 2047064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 572996 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy feed
Number of subjects: 40
Study 572996 — intervention group
Group type: COMPARATOR
Intervention: Humanized cow's milk formula
Number of subjects: 40
Study 30179928 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct anterior approach
Number of subjects: 164
Study 30179928 — intervention group
Group type: COMPARATOR
Intervention: Direct lateral approach
Number of subjects: 164
Study 30179928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 164
Study 27338807 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant (2.5 to 75 mg) administered for 14 consecutive nights
Number of subjects: 0
Study 27338807 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant (2.5, 10, or 25 mg) administered for 14 consecutive nights
Number of subjects: 0
Study 27338807 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 14 consecutive nights
Number of subjects: 0
Study 26637091 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity test (BRS) in supine position (L-BRS)
Number of subjects: 60
Study 26637091 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity test (BRS) in standing position (S-BRS)
Number of subjects: 60
Study 26637091 — intervention group
Group type: COMPARATOR
Intervention: Baroreflex sensitivity test (BRS)
Number of subjects: 60
Study 23711230 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation (ASV)
Number of subjects: 48
Study 23711230 — intervention group
Group type: COMPARATOR
Intervention: Volume-cycled ventilation (VCV)
Number of subjects: 48
Study 20537347 — intervention group
Group type: EXPERIMENTAL
Intervention: P duration greater than 110 milliseconds
Number of subjects: 339
Study 20537347 — intervention group
Group type: EXPERIMENTAL
Intervention: Other ECG parameters (P to PR segment ratio, P terminal force in lead V1, P wave area, bifid, and biphasic P wave)
Number of subjects: 339
Study 20110022 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin/Fenofibrate FDC (40 mg/100 mg)
Number of subjects: 220
Study 20110022 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 220
Study 20110022 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate 145 mg
Number of subjects: 220
Study 16396872 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive education and home visiting for families of children with BLLs 15 to 19 microg/dL
Number of subjects: 175
Study 16396872 — intervention group
Group type: COMPARATOR
Intervention: Customary care (1 or 2 educational visits)
Number of subjects: 175
Study 15623686 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg CAB once daily
Number of subjects: 85
Study 15623686 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg CAB once daily
Number of subjects: 85
Study 15623686 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg CAB once daily
Number of subjects: 85
Study 15623686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 15623686 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB therapy (mean dose of 2.2 mg per day over 1 year)
Number of subjects: 85
Study 11242379 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with distraction and fusion using Harrington rods
Number of subjects: 283
Study 11242379 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace treatment
Number of subjects: 283
Study 11242379 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 age- and gender-matched individuals)
Number of subjects: 283
Study 9260078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cola at 33 mg/serving
Number of subjects: 11
Study 9260078 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee at 33 mg/serving
Number of subjects: 11
Study 9260078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cola at 100 mg/serving
Number of subjects: 11
Study 9260078 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee at 100 mg/serving
Number of subjects: 11
Study 9260078 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated beverages (both cola and coffee)
Number of subjects: 11
Study 9260078 — intervention group
Group type: COMPARATOR
Intervention: Noncaffeinated beverages
Number of subjects: 11
Study 8501457 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg
Number of subjects: 125
Study 8501457 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 6 mg
Number of subjects: 125
Study 8501457 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 35 mg
Number of subjects: 125
Study 8501457 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 65 mg
Number of subjects: 125
Study 8501457 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 125
Study 8501457 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 125
Study 3551621 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM Dance Program (experimental group)
Number of subjects: 33
Study 3551621 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional exercise and rest regimens)
Number of subjects: 33
Study 28624647 — intervention group
Group type: EXPERIMENTAL
Intervention: FNA
Number of subjects: 274
Study 28624647 — intervention group
Group type: COMPARATOR
Intervention: FNB
Number of subjects: 274
Study 27740603 — intervention group
Group type: EXPERIMENTAL
Intervention: Aronia-citrus juice
Number of subjects: 16
Study 27740603 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 16
Study 23767786 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral smoking intervention with AS reduction component
Number of subjects: 169
Study 23767786 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive behavioral smoking intervention
Number of subjects: 169
Study 24355229 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled crenotherapy with salso-sulphide water
Number of subjects: 107
Study 24355229 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (NaCl 0.9 percent)
Number of subjects: 107
Study 20494043 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 4326
Study 20494043 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 4326
Study 18003666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of folic acid (2.5 mg), vitamin B6 (50 mg), and vitamin B12 (1 mg) daily for 5 years
Number of subjects: 619
Study 18003666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study 18003666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of folic acid, vitamin B6, and vitamin B12
Number of subjects: 619
Study 15910349 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (0.2 mg.kg‐1 bolus followed by 5 microg.kg‐1.min‐1 infusion)
Number of subjects: 30
Study 15910349 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 30
Study 12909221 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM CCRT (600 mg/m(2)/wk for 6 weeks)
Number of subjects: 34
Study 12909221 — intervention group
Group type: COMPARATOR
Intervention: 5-FU CCRT (500 mg/m(2)/d for 3 days repeated every 2 weeks for 6 weeks)
Number of subjects: 34
Study 10745429 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 350
Number of subjects: 20
Study 10745429 — intervention group
Group type: COMPARATOR
Intervention: Iopentol 350
Number of subjects: 20
Study 8886549 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 409
Study 8886549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 2037068 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimaeric protein SP1-Kox 29
Number of subjects: 0
Study 2037068 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized oligonucleotides (GGG NNNN GGC)
Number of subjects: 0
Study 6132082 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (50‐200 micrograms/kg/h)
Number of subjects: 28
Study 6132082 — intervention group
Group type: COMPARATOR
Intervention: Intravenous frusemide (1 mg/kg)
Number of subjects: 28
Study 31931250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg slow pumping dose, maintained at 0.3 μg/kg·h intraoperatively)
Number of subjects: 88
Study 31931250 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (same amount as dexmedetomidine, same infusion method)
Number of subjects: 88
Study 30851250 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Number of subjects: 20
Study 30851250 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement
Number of subjects: 20
Study 30851250 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall implant survival
Number of subjects: 20
Study 29410607 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (MTSZ) group, received a 1-month music intervention series combined with antipsychotic drugs
Number of subjects: 36
Study 29410607 — intervention group
Group type: COMPARATOR
Intervention: No-music intervention (UMTSZ) group, treated solely with antipsychotic drugs
Number of subjects: 36
Study 29410607 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (MTSZ) group
Number of subjects: 36
Study 25500685 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 20 mg/day
Number of subjects: 1133
Study 25500685 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 1133
Study 25500685 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 1133
Study 25500685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1133
Study 23348009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone (400 mg)
Number of subjects: 31
Study 23348009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21081550 — intervention group
Group type: EXPERIMENTAL
Intervention: varespladib methyl 500 mg once daily
Number of subjects: 135
Study 21081550 — intervention group
Group type: EXPERIMENTAL
Intervention: varespladib methyl 250 mg once daily
Number of subjects: 135
Study 21081550 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 135
Study 19398260 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 576
Study 19398260 — intervention group
Group type: COMPARATOR
Intervention: Open myomectomy
Number of subjects: 576
Study 16189179 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 7
Study 16189179 — intervention group
Group type: COMPARATOR
Intervention: l-arginine/GHRP-2
Number of subjects: 7
Study 16189179 — intervention group
Group type: COMPARATOR
Intervention: GHRH/GHRP-2
Number of subjects: 7
Study 16189179 — intervention group
Group type: COMPARATOR
Intervention: l-arginine/GHRH
Number of subjects: 7
Study 12574185 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (2 mg/d)
Number of subjects: 26
Study 12574185 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol (patch delivering 50 microg/d)
Number of subjects: 26
Study 12574185 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study 10562937 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or = 90 mmHg
Number of subjects: 806
Study 10562937 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or = 85 mmHg
Number of subjects: 806
Study 10562937 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or = 80 mmHg
Number of subjects: 806
Study 10562937 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 806
Study 8889112 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (group 1, n = 27)
Number of subjects: 92
Study 8889112 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (group 2, n = 34)
Number of subjects: 92
Study 8889112 — intervention group
Group type: COMPARATOR
Intervention: Control (group 3, n = 31)
Number of subjects: 92
Study 1984327 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic radiography
Number of subjects: 385
Study 1984327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic endoscopy
Number of subjects: 385
Study 6339923 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (200 mg per dose) five times daily for 10 days
Number of subjects: 48
Study 6339923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6339923 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 48
Study 30503296 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical IMRT-based stereotactic body radiotherapy (SBRT) at dose levels 3-4 (42-60 Gy)
Number of subjects: 32
Study 30503296 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical IMRT-based stereotactic body radiotherapy (SBRT)
Number of subjects: 32
Study 29777744 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 11
Study 29777744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 26573754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm A (workshop + audit report)
Number of subjects: 0
Study 26573754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm B (workshop + audit report + delayed prescribing evidence)
Number of subjects: 0
Study 26573754 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25131735 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation (NVAS)
Number of subjects: 5141
Study 25131735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5141
Study 22260307 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior suspension and posterior reconstruction during RALP (group B)
Number of subjects: 72
Study 22260307 — intervention group
Group type: COMPARATOR
Intervention: Standard RALP (group A)
Number of subjects: 72
Study 22260307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 19499849 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg/die and gamma-linolenic acid (GLA) 360 mg/die
Number of subjects: 112
Study 19499849 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin B preparation (Vit B6 150 mg, Vit B1 100 mg, Vit B12 500 microg daily)
Number of subjects: 112
Study 19499849 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) and gamma-linolenic acid (GLA)
Number of subjects: 112
Study 19499849 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin B preparation
Number of subjects: 112
Study 17952842 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg
Number of subjects: 16
Study 17952842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16366763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (100 mg)
Number of subjects: 14
Study 16366763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (200 mg)
Number of subjects: 14
Study 16366763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (300 mg)
Number of subjects: 14
Study 16366763 — intervention group
Group type: COMPARATOR
Intervention: Cocaine (0 mg)
Number of subjects: 14
Study 12169865 — intervention group
Group type: EXPERIMENTAL
Intervention: L-threo-3,4-dihydroxyphenylserine (L-DOPS) 400 mg
Number of subjects: 74
Study 12169865 — intervention group
Group type: EXPERIMENTAL
Intervention: L-threo-3,4-dihydroxyphenylserine (L-DOPS) 200 mg or 400 mg
Number of subjects: 74
Study 12169865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 9459382 — intervention group
Group type: EXPERIMENTAL
Intervention: RS2 (uncooked high‐amylose cornstarch)
Number of subjects: 24
Study 9459382 — intervention group
Group type: EXPERIMENTAL
Intervention: RS3 (extruded and retrograded high‐amylose cornstarch)
Number of subjects: 24
Study 9459382 — intervention group
Group type: COMPARATOR
Intervention: Glucose (control)
Number of subjects: 24
Study 8641325 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered sublingual captopril (pH 7)
Number of subjects: 14
Study 8641325 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered sublingual captopril
Number of subjects: 14
Study 8641325 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered and unbuffered sublingual captopril
Number of subjects: 14
Study 2354483 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 113
Study 2354483 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release verapamil
Number of subjects: 113
Study 345586 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride (Ditropan)
Number of subjects: 0
Study 345586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31142196 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning an individualized song
Number of subjects: 12
Study 31142196 — intervention group
Group type: COMPARATOR
Intervention: Non-training period
Number of subjects: 12
Study 29110707 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level intervention
Number of subjects: 0
Study 29110707 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25840296 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 25
Study 25840296 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia associated with cryoanalgesia
Number of subjects: 25
Study 23903997 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD patients
Number of subjects: 20
Study 23903997 — intervention group
Group type: EXPERIMENTAL
Intervention: DLS patients
Number of subjects: 20
Study 23903997 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 20
Study 21739693 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion group (warming needle moxibustion, once a day for 10 days)
Number of subjects: 105
Study 21739693 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion group
Number of subjects: 105
Study 21739693 — intervention group
Group type: COMPARATOR
Intervention: Chinese medicine group (Simo Decoction oral solution, three times daily for 10 days)
Number of subjects: 105
Study 21739693 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment group
Number of subjects: 105
Study 18785964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of triamcinolone acetonide (4 mg)
Number of subjects: 16
Study 18785964 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival saline (control)
Number of subjects: 16
Study 16723428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornish Program for Reversing Heart Disease
Number of subjects: 84
Study 16723428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR)
Number of subjects: 84
Study 16723428 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 12082498 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercury and aneroid sphygmomanometers
Number of subjects: 131
Study 12082498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphygmomanometers
Number of subjects: 131
Study 12082498 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure recording audit
Number of subjects: 131
Study 10434237 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1200 mg)
Number of subjects: 32
Study 10434237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7844679 — intervention group
Group type: EXPERIMENTAL
Intervention: Unwashed, older packed red blood cells
Number of subjects: 100
Study 7844679 — intervention group
Group type: COMPARATOR
Intervention: Washed, younger packed red blood cells
Number of subjects: 100
Study 2193272 — intervention group
Group type: EXPERIMENTAL
Intervention: Presacral neurectomy
Number of subjects: 26
Study 2193272 — intervention group
Group type: COMPARATOR
Intervention: Resection of endometriosis (Control)
Number of subjects: 26
Study 396930 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin (Baypen)
Number of subjects: 701
Study 29746150 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-bundle (TB) anatomic reconstruction using semiconjoint tendon (SCT) and coracoacromial ligament (CAL)
Number of subjects: 12
Study 29746150 — intervention group
Group type: COMPARATOR
Intervention: Modified Weaver-Dunn (WD) reconstruction
Number of subjects: 12